IMCIVREE
setmelanotidepeptideMC4R agonist
Bardet-Biedl Syndrome Obesity
Approved
1 program·1 trial·View drug →
DashboardSell17,448$27.71−$483.5KSell11,451$34.75−$397.9KBuy16,715$26.37+$440.8KBuy13,254$26.19+$347.2KOption ex.13,146$32.57$428.1KSell73,182$25.58−$1.9MAward997$33.77$33.7KAward3,990$26.11$104.2K NephrologyResearch Grant$566.9K7NephrologyResearch Grant$405.0K4CardiologyResearch Grant$381.6K7CardiologyCo-Investigator$355.8K4NephrologyCo-Investigator$351.2K3NephrologyCo-Investigator$348.4K2NephrologyResearch Grant$315.1K5CardiologyEquity / Ownership$219.3K3CardiologyResearch Grant$72.3K2CardiologySpeaking$9.0K3
RYTMNASDAQ
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. · Boston, MA · founded 2008
Rhythm Pharmaceuticals is a Boston biotech focused on rare genetic forms of obesity caused by defects in the melanocortin signaling pathway, which regulates hunger and energy balance. Lead drug IMCIVREE (setmelanotide) is an MC4 receptor agonist approved in the US and EU for several ultra-rare obesity syndromes, and the company is studying it across additional pediatric and adult populations.
- Lead asset
- IMCIVREE · Approved · Bardet-Biedl Syndrome Obesity
- peptide · MC4R agonist
- Pipeline
- 2 drugs · 2 programs
- 2 Obesity / GLP-1
- Modalities
- peptide×2
FocusRare DiseaseObesity / GLP-1
$75.00-19.73%1Y
RYTM · daily close · illustrative · 2 catalysts marked
AdCom+30%Conf.+4%
1Y high$96.561Y low$75.00range$21.56(29%)past catalysts
Peers in this space
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase2programs
- Preclin0
- Ph10
- Ph21
- Ph30
- Filed0
- Approved1
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Dec 26, 2025AdComIMCIVREE — Advisory Committee — 12–2 Vote in FavorPositive+30.3%+20.3%+29.1%
Sep 27, 2025Conf.IMCIVREE — ASH Late-Breaker — Updated SurvivalPositive+3.6%+4.7%+5.8%
Aug 3, 2024AdComRM-718 — Advisory Committee — 12–2 Vote in FavorPositive+15.4%+18.1%+17.3%
Jul 4, 2024ReadoutRM-718 — Phase 2b Topline Met Primary EndpointPositive+28.5%+43.3%+26.0%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 8 transactions · 8 insiders
Net flow
−$2.0M
Buys
$787.9K
2 txns
Sells
$2.8M
3 txns
Largest
−$1.9M
CEO sell
Net flow per quarter · last 8Q
10 txns · sum −$1.78M
24Q325Q125Q326Q126Q2
buys · $971Ksells · $2.75M
Insider · roleActionSharesPriceValueDate
J. Mendoza
SVP
Apr 23, 2026
N. Tanaka
CSO
Apr 20, 2026
M. Mendoza
EVP
Apr 18, 2026
B. Lindberg
CFO
Apr 13, 2026
K. Nguyen
CMO
Apr 7, 2026
E. Kowalski
CEO
Apr 1, 2026
B. Chen
Director
Mar 30, 2026
P. Reyes
Director
Feb 20, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
6 trades · 6 members
Est. net flow
−$6.35M
midpoint · brackets only
Buys
2
Sells
4
Party mix
2 D3 R1 I
Member · chamberActionBracket~ midpointOwnerDate · disclosure
R
Sell$1K–$15K~$8KspouseSen. B. Tucker
Senate · TN
Mar 6, 2026
filed +34d
R
Sell$1.00M–$5.00M~$3.00MselfRep. M. Hartwell
House · FL
Feb 12, 2026
filed +15d
D
Buy$250K–$500K~$375KspouseSen. C. Walsh
Senate · NY
Jan 21, 2026
filed +2d
I
Sell$1.00M–$5.00M~$3.00MselfRep. R. Müller
House · VT
Aug 20, 2025
filed +10d
R
Buy$15K–$50K~$33KselfRep. G. Ostrom
House · OH
Jul 2, 2025
filed +31d
D
Sell$500K–$1.00M~$750KselfSen. A. Reyes
Senate · CA
May 25, 2025
filed +38d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
5 ETFs hold the position
Held by ETFs
$23.8M
aggregate position
Of market cap
0.61%
aggregate ETF share
Top holder
XBI0.14%
SPDR S&P Biotech ETF
TickerETF · familyThemeNAV% of NAVPosition
XBIBroad biotech$7.90B0.14%$11.1M
SPDR S&P Biotech ETF
SPDR
IBBBroad biotech$8.40B0.08%$6.7M
iShares Biotechnology ETF
iShares
SBIOSmall-cap biotech$110.0M3.31%$3.6M
ALPS Medical Breakthroughs ETF
First Trust
BBCSmall-cap biotech$60.0M3.55%$2.1M
Virtus LifeSci Biotech Clinical Trials
WisdomTree
PBEBroad biotech$175.0M0.16%$280K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
10 physicians paid · 40 disclosed records
Total 2025+2024
$3.02M
YoY
+33%
Research Grant$1.29MCo-Investigator$936.2KEquity / Ownership$564.5KConsulting$163.7KSpeaking$59.8KTravel & Lodging$12.8KFood & Beverage$1.3K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Nadia Nakamura
Duke University
Dr. Ahmed Park
Yale Medical
Dr. Devon Chen
Penn Medicine
Dr. Henry Patel
Yale Medical
Dr. Nadia Hoffman
Duke University
Dr. Vivian Müller
Vanderbilt
Dr. Marcus Park
Stanford Medicine
Dr. Anita Murphy
Penn Medicine
Dr. Priya Chen
University of Michigan
Dr. Yuki Andersson
Johns Hopkins
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$414K disclosed · 3 firms engaged
YoY change
+19%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
K&L Gates$193K
8 quarters active
Holland & Knight$125K
6 quarters active
Van Scoyoc Associates$96K
5 quarters active
Top issues lobbied
- Drug Supply Chain Security Act$189K
- Prescription Drug User Fee programs$64K
- Orphan Drug Act amendments$64K
- Patent Trial and Appeal Board reforms$48K
- BIOSIM Act / Biosimilars$48K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
3 awards · 1 agency
Total awarded
$66.7M
across all programs
Active
$66.7M
option periods incl.
Top agency
NIH / NCI$66.7M
largest active: Immuno-Oncology Combination Trial Sponsorship
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NCIactive$5.9MNov 2025→ May 2027
Immuno-Oncology Combination Trial Sponsorship
Cooperative Agreement · NIH-26589546
NIH / NCIactive$49.2MMar 2025→ Nov 2028
Immuno-Oncology Combination Trial Sponsorship
Cooperative Agreement · NIH-80236714
NIH / NCIactive$11.6MMay 2024→ Mar 2027
Immuno-Oncology Combination Trial Sponsorship
Cooperative Agreement · NIH-59818536
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
2 granted · 1 pending
Total in portfolio
3
Granted in last 12mo
1
Expiring < 2yr
0
Nearest expiry
Apr 2036
Patent #Title · inventor · drugTypeStatus · filedExpiry
11,203,050Process
Scalable cell-line manufacturing for RM-718
T. Greene + 2 · RM-718
grantedfiled Apr 2023
exp. Apr 2043
17.0y left
US 2020/3886730 A1Composition of Matter
Antibody-drug conjugates with novel linkers for RM-718
E. Tanaka · RM-718
pendingfiled Apr 2020
in prosecution
11,958,844Formulation
Sustained-release oral compositions of IMCIVREE
K. Romano · IMCIVREE
grantedfiled Apr 2016
exp. Apr 2036
10.0y left
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
5 items from 5 categories
regulatory1clinical1corporate1earnings1partnership1
28d ago
EMA validates RYTM's Marketing Authorization Application for IMCIVREE
FierceBiotech·regulatory
1mo ago
RYTM presents RM-718 data at major medical conference
FierceBiotech·clinical
2mo ago
RYTM announces $189 million private placement
Business Wire·corporate
2mo ago
RYTM provides quarterly cash position and operating runway update
Business Wire·earnings
3mo ago
RYTM expands co-development partnership for next-gen pipeline
Business Wire·partnership
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$75.00
Open
$74.85
Day Δ
+0.15
+0.20%
Day range
$74.29 – $75.56
52W range
$75.00 – $96.56
Avg daily volume
489K
Valuation & ownership
Enterprise value
$3.7B
Shares out
52.00M
Float
48.36M
Insider %
5.72%
Institutional %
55.72%
Beta
2.22
vs SPY · 52w
Balance sheet & burn
Cash + invest
$345M
Total debt
$72M
Debt / equity
6.72
Cash burn / Q
$42M
R&D spend TTM
$155M
45% of cash
ATM available
$663M
dilution risk
Earnings
EPS latest
$-0.07
EPS Δ vs prior
+0.12
EPS estimate
$-0.15
next quarter
EPS prior
$-0.19
Next earnings
Jun 19, 2026
Rev guidance
$27M